QLP2117 / Qilu Pharma, Sound Biologics - LARVOL DELTA

Updated data from a phase I trial of QLP2117 in patients with advanced solid tumors (ESMO Asia 2025) - P1 | "QLP2117 showed manageable safety, tolerability, and preliminary antitumor efficacy in pts with advanced solid tumors, which is worthy of further exploration."

Clinical • Metastases • P1 data • Colorectal Cancer • Gastric Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CCR8

QLP2117-201: A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients (clinicaltrials.gov) - P1/2 | N=90 | Not yet recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.

New P1/2 trial • Oncology • Solid Tumor

Safety, tolerability and preliminary efficacy of QLP2117, a novel CCR8 antibody, in patients with advanced solid tumors: results from a dose-escalation phase 1a clinical trial (SITC 2024) - "Conclusions QLP2117 showed manageable safety and tolerability in patients with solid tumor. The efficacy of QLP2117 warranted further exploration, particularly in combination with anti-PD-1 agents."

Clinical • IO biomarker • Late-breaking abstract • Metastases • P1 data • Colorectal Cancer • Nasopharyngeal Carcinoma • Oncology • Solid Tumor • CCR8

QLP2117-101: A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=180 | Recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor

A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=180 | Not yet recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.

Metastases • New P1 trial • Oncology • Solid Tumor